Your browser doesn't support javascript.
loading
Rapid decline of Zika virus NS1 antigen-specific antibody responses, northeastern Brazil.
Moreira-Soto, Andres; de Souza Sampaio, Gilmara; Pedroso, Célia; Postigo-Hidalgo, Ignacio; Berneck, Beatrice Sarah; Ulbert, Sebastian; Brites, Carlos; Netto, Eduardo Martins; Drexler, Jan Felix.
Afiliação
  • Moreira-Soto A; Charité-Universitätsmedizin Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Institute of Virology, Berlin, Germany.
  • de Souza Sampaio G; Universidade Federal da Bahia, Salvador, Bahia, Brasil.
  • Pedroso C; Universidade Federal da Bahia, Salvador, Bahia, Brasil.
  • Postigo-Hidalgo I; Charité-Universitätsmedizin Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Institute of Virology, Berlin, Germany.
  • Berneck BS; Department of Immunology, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
  • Ulbert S; Department of Immunology, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
  • Brites C; Universidade Federal da Bahia, Salvador, Bahia, Brasil.
  • Netto EM; Universidade Federal da Bahia, Salvador, Bahia, Brasil.
  • Drexler JF; Fundação José Silveira, Salvador, Bahia, Brasil.
Virus Genes ; 56(5): 632-637, 2020 Oct.
Article em En | MEDLINE | ID: mdl-32542479
ABSTRACT
Zika virus (ZIKV) is a positive-stranded RNA virus within the Flaviviridae family. After decades of circulation in Asia, ZIKV was introduced to Brazil in 2014-2015, associated with a rise in congenital malformations. Unlike the genetically related dengue virus (DENV), ZIKV constitutes only one serotype. Although assumed that ZIKV infection may engender lifelong immunity, the long-term kinetics of ZIKV antibody responses are unclear. We assessed long-term kinetics of ZIKV NS1-IgG response in 144 individuals from 3 different subpopulations HIV patients, tuberculosis patients and healthy individuals first tested in 2016 and retested 1.5-2 years after the 2015-2016 ZIKV epidemic in Salvador de Bahia, Brazil, using a widely distributed NS1-based commercial ELISA. The seropositivity in 2016 reached 59.0% (85/144, 95% confidence interval (CI) 50.7-66.7%), and decreased to 38.6% (56/144, CI 31.3-47.0%) 1.5-2 years later. In addition, the median ZIKV NS1-ELISA reactivity for individuals that remained positive in both timepoints significantly decreased from a ratio of 4.4 (95% CI 3.8-5.0) to 1.6 (95% CI 1.6-1.9) over the 2-year interval (Z - 6.1; p < 0.001) irrespective of the subpopulation analyzed. Initial 2016 DENV antibody response was non-significant between groups, suggesting comparable DENV background. The high 20.6% seroreversion suggest that widely used serologic tests may fail to account a considerable proportion of past ZIKV infections in flavivirus endemic countries. In addition, ZIKV immunity might be shorter-lived than previously thought, which may contribute to local ZIKV resurgence once individual immune responses wane sufficiently to reduce community protective immunity in addition to birth and migration.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2020 Tipo de documento: Article